HomeAI · summaries
Storia in 4 fonti
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…
- ·
endpoints.news
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
- ·
fiercepharma.com
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an…
- ·
statnews.com
AstraZeneca picks up FDA approval for hypertension drug
The China question, FDA leadership shakeups, and other biotech news from The Readout